Recent meaningful negative changes in fundamentals have impacted Medifast Inc. (NYSE: MED): significant quarterly sales deceleration occurred, the consensus estimate for December, 2024 decreased significantly, and the consensus estimate for December, 2025 decreased significantly.
Medifast Inc. (NYSE: MED) suffers from exceptional negative changes in investment behavior: negative upside/downside volume developed, and the stock fell on very heavy volume.
In light of these highly negative signals we are reviewing our current Overall Rating of F. We would continue to view the shares with caution pending completion of this review in the next several days.
Current PriceTarget Research Rating
MED’s future returns on capital are forecasted to exceed the cost of capital. Accordingly, the company is expected to continue to be a Value Builder.
Medifast has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing inconsistent signals. Medifast has a neutral Appreciation Score of 44 but a very low Power Rating of 1, resulting in the Lowest Value Trend Rating.
Recent Price Action
On 6/21/24, Medifast Inc. (NYSE: MED) stock declined by -2.6%, closing at $20.03. Moreover, this decline was accompanied by exceptionally high trading volume at 858% of normal. Relative to the market the stock has been extremely weak over the last nine months and has declined -3.3% during the last week.
Be the first to comment